Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17147
Title: Inclusion of elderly patients in oncology clinical trials.
Authors: Le Saux, O;Falandry, C;Gan, Hui K;You, B;Freyer, G;Péron, J
Affiliation: Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, Oullins, France
Geriatric Oncology Department, Centre Hospitalier Lyon Sud, Pierre-Bénite CarMen Biomedical Research Laboratory (Cardiovascular Diseases, Metabolism, Diabetology and Nutrition), INSERM UMR 1060, Université de Lyon, Oullins, France
Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia
Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, Villeurbanne, France
CNRS, UMR 5558 Biometry and Evolutionary Biology Laboratory, Université Lyon 1, Villeurbanne, France
Statistics Unit, Hospices Civils de Lyon, Pierre-Bénite, Villeurbanne, France
Lyon 1 University, EMR 3738, Faculté de Médecine Lyon-Sud, Oullins, France
Issue Date: 2016
EDate: 2016-06-29
Citation: Annals of oncology : official journal of the European Society for Medical Oncology 2016; 27(9): 1799-1804
Abstract: Physicians need clinical trials assessing benefits and harms of treatments to avoid under-treatment or over-treatment of elderly patients. The main objectives of this report were to examine how data regarding elderly oncology patients were presented in medical literature; and to assess the evolution of this presentation between two time periods. All phases I, II and III trials dedicated to the treatment of cancer among elderly patients published between 2001 and 2004 and between 2011 and 2014 were reviewed. All phase III clinical trials assessing cancer treatments among adults in the same periods were also reviewed to evaluate potential subgroup analyses in elderly patients in these studies. Key characteristics of interest were extracted by two investigators before descriptive and comparative analyses were undertaken. A total of 1084 trials were included: 366 and 718 from the first and second time period, respectively. Twenty-seven and 193 of these trials were phase I and II trials dedicated to elderly or frail patients, respectively. A large proportion of phase III trials published between 2011 and 2014 reported at least one analysis dedicated to elderly patients (46.7%) versus 19.3% during the first time period. The use of subgroup analyses of elderly patients in phase III trials was the most frequent source of information. Subgroup analyses were more frequent among trials with industrial funding, trials published in high impact factor journal, intercontinental trials and trials with large sample size. The age threshold defining the elderly subgroup increased over time. Elderly patients have become a topic of interest during the past decade. However, data available are mostly extracted from subgroup analyses, which can only be regarded as preliminary evidence.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17147
DOI: 10.1093/annonc/mdw259
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/27358382
Type: Journal Article
Subjects: clinical trials
geriatric oncology
neoplasms
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.